Close menu




June 23rd, 2022 | 11:35 CEST

Takeover fantasy: +50% in Valneva shares, and what are BioNTech and Defence Therapeutics doing?

  • Biotechnology
  • Pharma
Photo credits: pixabay.com

Tension is rising in the biotech sector as the takeover merry-go-round spins faster and has now hit Valneva. Pfizer's entry caused the stock to explode 50% in three trading days. Earlier, Pfizer had announced it would acquire migraine specialist Biohaven for USD 11.6 billion. Other pharmaceutical giants are also active: Halozyme wants to swallow Antares Pharma, a specialist in urology and endocrinology, for USD 960 million. The acquisition of Sierra Oncology is costing GlaxoSmithKline around USD 1.9 billion. Like Valneva, Defence Therapeutics is about to start important trials and could attract a major partner. A takeover of BioNTech is unlikely, but the flagship German biotech should also benefit from improved sentiment in the industry. The coming week should be operationally exciting for shareholders.

time to read: 3 minutes | Author: Fabian Lorenz
ISIN: VALNEVA SE EO -_15 | FR0004056851 , BIONTECH SE SPON. ADRS 1 | US09075V1026 , DEFENCE THERAPEUTICS INC | CA24463V1013

Table of contents:


    Defence Therapeutics: With a full pipeline in the takeover carousel

    Things could get exciting for Defence Therapeutics in the coming months. The shares of the Canadian biotech company have lost significantly in the stock market quake of recent weeks. Yet it has an innovative platform and a full product pipeline with positive study results already reported most recently at the end of May. Three clinical trials are to be started by the beginning of 2023. This could be the right time for a pharma giant to get its foot in the door with a first investment - similar to what Pfizer just did with Valneva. Fittingly, the investment bank Canaccord Genuity outlined the Company's current situation in a detailed study the day before yesterday. Perhaps to excite a potential partner?

    The goal of Defence Therapeutics is to develop universal vaccines. To that end, the Canadians have developed an AccumTM drug booster platform. The platform, patented in the USA, allows antibody-drug conjugates (ADC) to be introduced into the diseased cells. The advantage: an up to 10-fold stronger effect compared to conventional ADC-based drugs. Based on the AccumTM platform, Defence Therapeutics is researching vaccines in oncology and infectious diseases, among others. From the cancer pipeline - including a cervical cancer vaccine - three clinical trials (phase 1) are scheduled to start by early 2023. Research is also being conducted into a universal vaccine against a wide range of cancers, giving the Company opportunities in a market worth billions. According to estimates, the vaccine market for immuno-oncology alone is expected to grow to around USD 105 billion by 2027. Also of interest is a COVID-19 vaccine, which has already led to a high level of protection in rodents. The golden days in this market may be over, but indications are that regular vaccinations will be useful- similar to influenza. The highlight of Defence Therapeutics is that the vaccine could presumably be offered as a nasal spray and thus set itself apart from the competition.

    BioNTech: New momentum?

    When it comes to COVID-19 and cancer research, BioNTech naturally comes into play. Indeed, the Company is not a takeover candidate; the founders and major shareholders seem to be too long-term oriented for that, and the market capitalization of around USD 30 billion also speaks against it. But the share should also benefit from the improved environment even if Goldman Sachs had renewed the rating to "Neutral" last week. The price target of USD 206 is clearly above the current price of the BioNTech share at USD 123. BioNTech has an extensive product pipeline to grow organically. In addition, Goldman brings BioNTech into play as an acquirer if an opportunity arises to exploit synergies. The biotech group has the necessary capital. The COVID-19 vaccine is also expected to generate billions in revenue this year.

    From an operational point of view, things will get exciting at BioNTech in the coming week. On June 29, the Wiesbaden-based company will host a virtual conference. There, there will be an update on the ongoing development work. In addition, BioNTech plans to provide insights into the scientific and technological innovations of the Company's own research engine.

    Valneva: Thanks to Pfizer +50% in three days

    Valneva shows how strongly takeover fantasies can drive a share price. Last Friday, the share was still trading at just under EUR 8. Then came the news that Pfizer would be taking a stake, and by Tuesday, the share had shot up to over EUR 12. So 50% in three trading days. And yesterday, in a weak market environment, the share fell just below the EUR 12 mark. Specifically, the deal calls for the US pharmaceutical group to pay around EUR 90.5 million for an 8% stake, corresponding to a shareholding price of EUR 9.49. In addition, milestone payments have been agreed upon. The entry is due to Valneva's Lyme disease vaccine candidate. Its Phase 3 trial is scheduled to start in the third quarter of the current year. Valneva sees blockbuster potential for the vaccine. As a result, investors' disappointment over the flop with the planned COVID-19 vaccine has evaporated for the time being. Because of the longer-than-planned approval and cancelled orders with the EU, Valneva shares had crashed by almost 80% from their high of around EUR 30 at the end of 2021.


    The acquisitions and investments by Big Pharma bring momentum to the biotech market. After the significant share price losses, BioNTech and Defence Therapeutics should also benefit from this. In the medium term, both will depend, of course, on the study results. Valneva's share price is already a good 20% above Pfizer's entry price. Since yesterday, the share has taken a healthy breather.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by Juliane Zielonka on September 29th, 2023 | 07:00 CEST

    Defence Therapeutics, Schott Pharma, Allianz Group: Focus on Innovation, Growth and Portfolio Optimization

    • Biotechnology
    • Pharma
    • Investments

    According to a recent study, biotech company Defence Therapeutics achieves twice the immune response of conventional mRNA therapies with its Accum® mRNA technology. That translates to fewer side effects and a more effective treatment. According to Precedence Research, the market size for mRNA therapeutics is projected to reach approximately USD 137.59 billion by 2032. It is expected to grow at a CAGR of 13.2% from 2023 to 2032. In order to inject these active ingredients, precision-fit medical vials are required, and Schott Pharma is ensuring this with their IPO launched on the German stock exchange this week, which could bring a valuation of around EUR 4 billion. The Allianz Group, on the other hand, is focusing on consolidation, selling its business in the Middle East and thus flushing around EUR 210 million cash into its coffers.

    Read

    Commented by André Will-Laudien on September 28th, 2023 | 08:05 CEST

    Attention: Extended correction - Buy the right stocks now! Bayer, Viva Gold, TUI, and BASF are on the list!

    • Mining
    • Gold
    • Pharma
    • chemicals
    • travel

    Higher inflation and rising interest rates - this connection should be clear to investors. The interest rate level in Germany has moved from negative territory to 2.77% in the 10-year range, but stocks continued to rise cheerfully. The party led to all-time highs of 16,528 points in July, but the fundamental situation of the companies deteriorated in parallel. Only after repeated warnings from the US Federal Reserve did the explosive NASDAQ also enter a correction. And it continues. Yesterday, the CEO of US investment bank JPMorgan, Dimon, warned that the world may not be prepared for 7% capital market interest rates. He and Dr. Jens Erhardt, the CEO of the asset management company DJE, warn of stronger setbacks on the stock markets. Some stocks have already undergone a strong correction. Here is a brief overview.

    Read

    Commented by Nico Popp on September 27th, 2023 | 07:10 CEST

    Rich as a Sheikh? Here is what's happening: Schott Pharma, BioNTech, Cardiol Therapeutics

    • Biotechnology
    • Pharma

    High-tech or add-on? When Schott Pharma's shares go public in Frankfurt on Thursday, investors are likely to have a clear opinion. The manufacturer of pharmaceutical packaging may be attracting significant interest precisely because its business model is clearly defined. But what sets Schott apart, and which companies in the pharmaceutical and biotech industry might also become interesting? We provide insights and deliver answers!

    Read